Bifidobacterium longum 070103 Fermented Milk Improve Glucose and Lipid Metabolism Disorders by Regulating Gut Microbiota in Mice

Background: Fermented milk is beneficial for metabolic disorders, while the underlying mechanisms of action remain unclear. This study explored the benefits and underlying mechanisms of Bifidobacterium longum 070103 fermented milk (BLFM) in thirteen-week high-fat and high-sugar (HFHS) fed mice using...

Full description

Saved in:
Bibliographic Details
Published in:Nutrients 2022-09, Vol.14 (19), p.4050
Main Authors: Jiang, Tong, Li, Ying, Li, Longyan, Liang, Tingting, Du, Mingzhu, Yang, Lingshuang, Yang, Juan, Yang, Runshi, Zhao, Hui, Chen, Moutong, Ding, Yu, Zhang, Jumei, Wang, Juan, Xie, Xinqiang, Wu, Qingping
Format: Article
Language:English
Subjects:
Bifidobacterium longum
Bifidobacterium longum fermented milk
Biotechnology
Blood glucose
Body weight
Cholesterol
Colon
Damage tolerance
Diet
Digestive system
Enzymes
Experiments
Fatty liver
fecal metabolites
Fermented milk products
Glucokinase
Glucose
Glucose metabolism
Glucose tolerance
glycolipid metabolism disorder
gut microbiota
Insulin
Insulin resistance
Intestinal microflora
Leptin
Lipid metabolism
Lipids
Liver
Low density lipoprotein
Metabolic disorders
Metabolites
Metabolomics
Microbiota
Milk
Probiotics
Proteins
Signs and symptoms
Steatosis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Fermented milk is beneficial for metabolic disorders, while the underlying mechanisms of action remain unclear. This study explored the benefits and underlying mechanisms of Bifidobacterium longum 070103 fermented milk (BLFM) in thirteen-week high-fat and high-sugar (HFHS) fed mice using omics techniques. Methods and results: BLFM with activated glucokinase (GK) was screened by a double-enzyme coupling method. After supplementing BLFM with 10 mL/kg BW per day, fasting blood glucose, total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and leptin were significantly reduced compared with the HFHS group. Among them, the final body weight (BW), epididymal fat, perirenal fat, and brown fat in BLFM group had better change trends than Lacticaseibacillus rhamnosus GG fermented milk (LGGFM) group. The amplicon and metabolomic data analysis identified Bifibacterium as a key gut microbiota at regulating glycolipid metabolism. BLFM reverses HFHS-induced reduction in bifidobacteria abundance. Further studies showed that BLFM significantly reduces the content of 3-indoxyl sulofphate associated with intestinal barrier damage. In addition, mice treated with BLFM improved BW, glucose tolerance, insulin resistance, and hepatic steatosis. Conclusion: BLFM consumption attenuates obesity and related symptoms in HFHS-fed mice probably via the modulation of gut microbes and metabolites.
ISSN:2072-6643
2072-6643
DOI:10.3390/nu14194050